CoronaryEditorial CommentAssessing Oral Beta-Blocker Therapy After Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: The Role of Observational Data∗
Key Words
Cited by (0)
Dr. Granger has received research funding from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic Foundation, Merck and Company, Pfizer Inc., Sanofi-Aventis, Takeda, The Medicines Company, and Bayer HealthCare; and consulting fees and/or honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-LaRoche, Lilly, Pfizer Inc., Sanofi-Aventis, Takeda, The Medicines Company, AstraZeneca, Daiichi Sankyo, Ross Medical Corporation, Janssen Pharmaceuticals, and Salix Pharmaceuticals. Dr. Rao has received research funding from Medtronic Foundation.
- ∗
Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.